NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) has announced that its CEO and Chairman, Prof. Jonathan Javitt, MD, MPH, will join a fireside chat at the upcoming BTIG Virtual Biotechnology Conference on July 29–30, 2025. The session, set for 8:00 a.m. EDT on July 30, will also feature Prof. Samuel Wilkinson, MD, from Yale School of Medicine, and BTIG Research Analyst Dr. Thomas Shrader. The discussion will center on the role of neuroplasticity in treating central nervous system (CNS) disorders, with a particular focus on the use of ketamine and other neuroplastic and psychedelic drugs for conditions such as depression, suicidality, and PTSD.
This conversation is significant as it sheds light on innovative treatments that could revolutionize the approach to mental health and chronic pain management. NRx Pharmaceuticals is at the forefront of developing therapies based on its NMDA platform, targeting CNS disorders with a focus on suicidal bipolar depression, chronic pain, and PTSD. The company's investigational drug, NRX-101, has been designated as a Breakthrough Therapy by the FDA for suicidal treatment-resistant bipolar depression and chronic pain, indicating its potential to address critical unmet medical needs.
Moreover, NRx Pharmaceuticals is in the process of filing a New Drug Application (NDA) for Accelerated Approval of NRX-101 for patients with bipolar depression and suicidality or akathisia. The drug also shows promise as a non-opioid treatment for chronic pain and a remedy for complicated urinary tract infections (UTI). Additionally, the company has initiated an NDA filing for NRX-100 (IV ketamine) for suicidal depression, leveraging data from clinical trials and French health authorities, underlining the global relevance and urgency of these treatments.
The participation of NRx Pharmaceuticals' leadership in this conference underscores the importance of advancing discussions on mental health treatments and the potential of psychedelic drugs to offer new hope to patients worldwide. The event represents a pivotal moment for stakeholders in the biotechnology and pharmaceutical industries, as well as for patients seeking alternatives to traditional therapies.
